BS PHARM KOREA Maps 7 Congresses in 2H 2026 for Distribution Push

BS PHARM KOREA’s portfolio covers skin boosters, hyaluronic acid fillers, regenerative formulations, and collagen-supporting products meant for use by qualified professionals under local regulations. The company also runs clinical evaluation programs with healthcare professionals to support product assessment and clinical feedback, it said.

The expansion comes as demand for non-invasive aesthetic treatments grows across emerging markets, particularly in the Middle East and Southeast Asia, where medical tourism and rising disposable incomes are boosting clinic visits. BS PHARM KOREA has not disclosed revenue or partner names tied to the initiative.

The company is privately held and does not publish financial results. Its focus on Congress attendance rather than direct sales suggests a wholesale model common among South Korean aesthetic device and injectable makers, which typically use distributors to navigate local regulatory and licensing hurdles.

No further details on specific partnership terms or revenue targets were provided.